Close Menu
Dailyza | Tech, Investments, Business & World News
  • Startups
  • Venture Capital
  • World
  • Economy
  • Politics
  • Science
  • Technology
  • Travel
  • Culture
Facebook X (Twitter) Instagram
Trending
  • STORM Therapeutics Secures $56M Funding for Groundbreaking Cancer Therapy
  • BioLamina Secures €20 Million Financing for Matrix Biology Innovation
  • Dailyza: UK Government Launches €573 Million Sovereign AI Initiative
  • X-energy Launches IPO Roadshow, Targets $814M for SMR Commercialization
  • Qalzy Launches Pre-Seed Round to Enhance AI Nutrition Scale
  • Upscale AI Secures $200M Series A to Enhance Data Centre Networking
  • urfuture Secures £1.7M Seed Funding to Revolutionize Hiring
  • Solidroad Secures $25M Series A to Revolutionize QA with AI
Dailyza | Tech, Investments, Business & World NewsDailyza | Tech, Investments, Business & World News
Saturday, April 18
  • Startups
  • Venture Capital
  • World
  • Economy
  • Politics
  • Science
  • Technology
  • Travel
  • Culture
Dailyza | Tech, Investments, Business & World News
Home»Venture Capital
Picus Capital team photo following €150 million preferred equity financing from Carlyle AlpInvest

Picus Capital lands €150M financing from Carlyle AlpInvest

19 December 2025 Venture Capital No Comments5 Mins Read
Share
Facebook Twitter LinkedIn Pinterest Email

Picus Capital has secured a fresh capital boost after closing a €150 million preferred equity financing provided by Carlyle AlpInvest, strengthening the firm’s ability to back early-stage companies across Europe and beyond. The deal underscores sustained investor appetite for established venture platforms even as fundraising remains uneven across the broader market.

A significant preferred equity deal for a venture platform

The €150 million financing is structured as preferred equity, a form of capital that can sit between common equity and debt in a firm’s capital stack. In practice, preferred equity can offer investors downside protection and priority economics while allowing the recipient to avoid some of the restrictive covenants that can come with traditional borrowing. For venture firms, it can provide long-duration capital aligned with the timeline of fund cycles and portfolio maturation.

For Picus Capital, the financing adds strategic flexibility at a moment when venture capital firms are balancing two competing realities: the need to support existing portfolio companies for longer, and the opportunity to invest into new cohorts of startups at valuations that, in many sectors, remain below the peaks of 2021.

Who is Carlyle AlpInvest and why it matters

Carlyle AlpInvest is known for investing across private equity and private markets, including GP-led solutions and structured capital. Its participation signals confidence in the durability of the venture asset class when paired with managers that have demonstrated sourcing strength and portfolio construction discipline.

Market participants have increasingly looked to structured deals—such as preferred equity or revenue-linked instruments—to bridge the gap between venture’s long holding periods and limited partner demands for more predictable outcomes. The financing suggests that institutional capital providers are willing to tailor instruments to back venture firms that can show consistent access to high-quality deal flow.

What the capital could enable for Picus Capital

While specific deployment details were not provided in the announcement, capital injections at the management-company level typically support a mix of growth priorities, including:

  • Expanding investment capacity and follow-on reserves for existing portfolios
  • Recruiting and retention of investing and operating talent
  • Building platform services for founders, such as hiring support, go-to-market guidance, and partnerships
  • Seeding new strategies or vehicles in adjacent stages or geographies

For founders, the practical impact can be meaningful: better-resourced venture firms can move faster on deals, provide more consistent follow-on support, and remain stable partners during volatile market periods.

Why preferred equity is gaining traction in venture capital

Preferred equity has become more visible in venture capital and private markets as managers seek non-dilutive or less-dilutive ways to fund operations and growth. Rising interest rates over the past two years made debt more expensive, while slower exit markets reduced near-term distributions. In that environment, preferred equity can serve as a middle path—providing capital without forcing a manager to raise a new fund prematurely or sell portfolio positions at unfavorable prices.

The structure can also align incentives: the investor receives preferential economics, while the venture firm maintains control and can continue executing its long-term strategy. For the broader ecosystem, this trend reflects a maturing market where financing solutions are becoming more specialized, mirroring the sophistication long present in private equity.

Context: a tougher fundraising market, but selective confidence

Venture fundraising has been more challenging since the post-pandemic boom cooled. Many limited partners have faced the “denominator effect,” where declines in public markets and slower private valuations skew portfolio allocations, reducing capacity for new commitments. At the same time, exits—through IPOs or large-scale acquisitions—have been slower, delaying liquidity.

Yet the Picus transaction indicates that capital is still available for managers perceived as resilient. In today’s environment, institutional backers often prioritize firms with clear differentiation: strong founder networks, repeatable sourcing, disciplined pricing, and the ability to help startups navigate extended runways and more demanding growth expectations.

What it signals for European startups

For Europe’s startup ecosystem, the deal is a reminder that venture capital is not uniformly constrained. While some funds are conserving cash and limiting new investments, others are shoring up balance sheets and preparing to deploy into sectors where conviction remains high—particularly AI algorithms, cybersecurity, fintech infrastructure, and vertical SaaS.

If more venture firms pursue structured capital solutions, founders could see a more stable funding environment at the early stages, even if late-stage rounds remain selective. The biggest impact may be on follow-on financing: well-capitalized firms can support promising companies through longer periods between priced rounds, helping them avoid down rounds or rushed fundraising processes.

What to watch next

Investors and founders will be watching for signals about how Picus Capital translates the financing into market activity: new hires, increased pace of deals, or expanded support for portfolio companies. The industry will also track whether similar preferred equity financings become more common among venture firms seeking to strengthen their platforms without relying solely on traditional fundraises.

As the exit environment slowly reopens and private markets recalibrate, transactions like this highlight a central theme of the current cycle: capital is still flowing, but it is flowing with more structure, more selectivity, and a sharper focus on long-term durability.

Dailyza will continue monitoring how the financing influences Picus’s investment cadence and what it may mean for founders competing for early-stage capital across Europe.

Previous ArticleCustom Software Drives Real-Time Inventory Control for Firms
Next Article TechCrunch Recaps 2025’s Biggest Data Breaches and Cyberattacks
Aden Erickson

Keep Reading

urfuture Secures £1.7M Seed Funding to Revolutionize Hiring

Dailyza: EU-Startups Summit 2026 to Ignite Innovation in Malta

Accel Secures $5 Billion to Fuel AI Startups Growth

Dailyza Announces EU-Startups Summit 2026 in Malta

Newfund Launches HEKA, Europe’s First €60M BrainTech Fund

GPO Fund’s Jeff Stewart on Strategic IPO Decisions for Startups

Add A Comment

Leave A Reply Cancel Reply

STORM Therapeutics Secures $56M Funding for Groundbreaking Cancer Therapy

Science 18 April 2026

STORM Therapeutics raises $56 million for Phase 2 trials of STC-15, the first METTL3 inhibitor targeting rare sarcoma cancers.

BioLamina Secures €20 Million Financing for Matrix Biology Innovation

urfuture Secures £1.7M Seed Funding to Revolutionize Hiring

CamGraPhIC Secures €211 Million Funding from European Commission

Dailyza: EU-Startups Summit 2026 to Ignite Innovation in Malta

Accel Secures $5 Billion to Fuel AI Startups Growth

EVANIUM Secures €2.2 Million to Advance OPTISOLV® Technology

Dailyza Announces EU-Startups Summit 2026 in Malta

Newfund Launches HEKA, Europe’s First €60M BrainTech Fund

GPO Fund’s Jeff Stewart on Strategic IPO Decisions for Startups

Dailyza Explores Compliance Challenges for Remote Startups in Europe

LightSeeds Secures €162k Funding to Boost CleanTech Solutions

Dailyza: Where Nordic Women-Founded Startups Face Capital Challenges

SiFive Secures $400M From NVIDIA, Apollo Ahead of IPO

EIGHT Portugal raises €3M Seed to scale video-first dating app

Dailyza | Tech, Investments, Business & World News
  • Startups
  • Contact
  • About Us
© 2026 Dailyza

Type above and press Enter to search. Press Esc to cancel.